Long Position on GILD @ $72.00 on 3/12/2020 (Momentum)

Gilead Sciences, Inc. (GILD) discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally.

The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections.

In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others.

The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. 

Shares are heading higher in an upward "trading channel." The 30-day moving average is shown in brown.

Last Trade: $72.00

Trading Range: $60.89 to $80.40

Stop Loss: $64.50

Target Price: $79.00

Updates

4/17/2020 9:32:06 AM

GILD closed at $85.00

Position closed on 4/17/2020 at price of $85.00 with a 18.06% gain in 36 days.

Back to Portfolio